IP Library Granted Patent US 8,034,843
Granted Patent B2
US 8,034,843 · App. 10/502,822 · Granted Oct 11, 2011

Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,034,843
App. No.
10/502,822
Granted
Oct 11, 2011
Kind
B2
Abstract

Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.

Claims (16)

1. A method of treating motion sickness in a mammal comprising administering a pharmaceutically acceptable amount of, or an extract consisting essentially of a pharmaceutically acceptable amount of, CBD and/or CBDA and/or the propyl variants CBDV and/or CBDVA, wherein the amount of CBD and/or CBDA and/or the propyl variants CBDV and/or CBDVA is greater than 50% of the total cannabinoid content, wherein the CBDA, and/or CBDVA and/or CBD and/or CBDV is/are present as a cannabis extract, and wherein the cannabis extract contains less than 10% (w/w) of other cannabinoids.

2. A method as claimed in claim 1 , wherein the cannabis extract contains less than 5% (w/w) of other cannabinoids.

3. A method as claimed in claim 1 , wherein the cannabis extract contains less than 2% (w/w) of other cannabinoids.

4. A method as claimed in claim 1 , wherein the other cannabinoids include THC or THCV.

5. A method as claimed in claim 1 , wherein the CBDA and/or CBDVA and/or CBD and/or CBDV is CBDA.

6. A method as claimed in claim 1 , wherein the CBDA and/or CBDVA and/or CBD and/or CBDV is CBDVA.

7. A method as claimed in claim 1 , wherein the CBDA and/or CBDVA and/or CBD and/or CBDV is CBD.

8. A method as claimed in claim 1 , wherein the CBDA and/or CBDVA and/or CBD and/or CBDV is CBDV.

9. A method as claimed in claim 1 , wherein the cannabis extract comprises 0.1-2% (w/w) of THC and/or THCA.

10. A method of treating motion sickness in a mammal comprising administering a cannabis extract consisting essentially of a pharmaceutically acceptable amount of CBD and/or CBDA and/or the propyl variants CBDV and/or CBDVA, wherein the cannabis extract comprises greater than 2% (w/w) of CBDA and/or CBDVA and/or CBD and/or CBDV, and wherein the cannabis extract contains less than 10% (w/w) of other cannabinoids.

11. A method as claimed in claim 10 , wherein the cannabis extract comprises greater than 5% (w/w) of CBDA and/or CBDVA and/or CBD and/or CBDV.

12. A method as claimed in claim 10 , wherein the cannabis extract comprises greater than 7% (w/w) of CBDA and/or CBDVA and/or CBD and/or CBDV.

13. A method as claimed in claim 10 , wherein the CBDA and/or CBDVA and/or CBD and/or CBDV is CBDA.

14. A method as claimed in claim 10 , wherein the CBDA and/or CBDVA and/or CBD and/or CBDV is CBDVA.

15. A method as claimed in claim 10 , wherein the CBDA and/or CBDVA and/or CBD and/or CBDV is CBD.

16. A method as claimed in claim 10 , wherein the CBDA and/or CBDVA and/or CBD and/or CBDV is CBDV.

Assignments (2)
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2005
From: WHITTLE, BRIAN; JAVID, FARIDEH AFSHIN
To: GW PHARMA LIMITED
Reel/Frame 016458/0070 →